Literature DB >> 15886205

Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail.

Minna Poukkula1, Aura Kaunisto, Ville Hietakangas, Konstantin Denessiouk, Tuire Katajamäki, Mark S Johnson, Lea Sistonen, John E Eriksson.   

Abstract

The caspase-8 inhibitor c-FLIP exists as two splice variants, c-FLIP(L) and c-FLIP(S), with distinct roles in death receptor signaling. The mechanisms determining their turnover have not been established. We found that in differentiating K562 erythroleukemia cells both c-FLIP isoforms were inducibly degraded by the proteasome, but c-FLIP(S) was more prone to ubiquitylation and had a considerably shorter half-life. Analysis of the c-FLIP(S)-specific ubiquitylation revealed two lysines, 192 and 195, C-terminal to the death effector domains, as principal ubiquitin acceptors in c-FLIP(S) but not in c-FLIP(L). Furthermore the c-FLIP(S)-specific tail of 19 amino acids, adjacent to the two target lysines, was demonstrated to be the key element determining the isoform-specific instability of c-FLIP(S). Molecular modeling in combination with site-directed mutagenesis demonstrated that the C-terminal tail is required for correct positioning and subsequent ubiquitylation of the target lysines. Because the antiapoptotic operation of c-FLIP(S) was not affected by the tail deletion, the antiapoptotic activity and ubiquitin-mediated degradation of c-FLIP(S) are functionally and structurally independent processes. The presence of a small destabilizing sequence in c-FLIP(S) constitutes an important determinant of c-FLIP(S)/c-FLIP(L) ratios by allowing differential degradation of c-FLIP isoforms. The conformation-based predisposition of c-FLIP(S) to ubiquitin-mediated degradation introduces a novel concept to the regulation of the death-inducing signaling complex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15886205     DOI: 10.1074/jbc.M504019200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

1.  ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2.

Authors:  Rosa Martín-Pérez; Maho Niwa; Abelardo López-Rivas
Journal:  Apoptosis       Date:  2012-04       Impact factor: 4.677

2.  Modeling reveals that dynamic regulation of c-FLIP levels determines cell-to-cell distribution of CD95-mediated apoptosis.

Authors:  Hannu T Toivonen; Annika Meinander; Tomoko Asaoka; Mia Westerlund; Frank Pettersson; Andrey Mikhailov; John E Eriksson; Henrik Saxén
Journal:  J Biol Chem       Date:  2011-02-15       Impact factor: 5.157

Review 3.  Chemistry and biology of rocaglamides (= flavaglines) and related derivatives from aglaia species (meliaceae).

Authors:  Sherif S Ebada; Neil Lajkiewicz; John A Porco; Min Li-Weber; Peter Proksch
Journal:  Prog Chem Org Nat Prod       Date:  2011

4.  A TNF- and c-Cbl-dependent FLIP(S)-degradation pathway and its function in Mycobacterium tuberculosis-induced macrophage apoptosis.

Authors:  Manikuntala Kundu; Sushil Kumar Pathak; Kuldeep Kumawat; Sanchita Basu; Gargi Chatterjee; Shresh Pathak; Takuya Noguchi; Kohsuke Takeda; Hidenori Ichijo; Christine B F Thien; Wallace Y Langdon; Joyoti Basu
Journal:  Nat Immunol       Date:  2009-07-13       Impact factor: 25.606

5.  Herpes simplex virus type 1 (HSV-1)-induced apoptosis in human dendritic cells as a result of downregulation of cellular FLICE-inhibitory protein and reduced expression of HSV-1 antiapoptotic latency-associated transcript sequences.

Authors:  Angela Kather; Martin J Raftery; Gayathri Devi-Rao; Juliane Lippmann; Thomas Giese; Rozanne M Sandri-Goldin; Günther Schönrich
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

6.  Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways.

Authors:  Haiyan Wang; Shanbao Cai; Aaron Ernstberger; Barbara J Bailey; Michael Z Wang; Wenjing Cai; W Scott Goebel; Magdalena B Czader; Colin Crean; Attaya Suvannasankha; Inna Shokolenkoc; Glenn L Wilson; Arthur R Baluyut; Lindsey D Mayo; Karen E Pollok
Journal:  Clin Cancer Res       Date:  2013-03-27       Impact factor: 12.531

Review 7.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.

Authors:  Ahmad R Safa; Travis W Day; Ching-Huang Wu
Journal:  Curr Cancer Drug Targets       Date:  2008-02       Impact factor: 3.428

8.  c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.

Authors:  John Kauh; Songqing Fan; Mingjing Xia; Ping Yue; Lily Yang; Fadlo R Khuri; Shi-Yong Sun
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

9.  TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.

Authors:  Josep Maria Lluis; Ulrich Nachbur; Wendy Diane Cook; Ian Edward Gentle; Donia Moujalled; Maryline Moulin; Wendy Wei-Lynn Wong; Nufail Khan; Diep Chau; Bernard Andrew Callus; James Edward Vince; John Silke; David Lawrence Vaux
Journal:  PLoS One       Date:  2010-01-08       Impact factor: 3.240

10.  Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells.

Authors:  D Mahalingam; A Natoni; M Keane; A Samali; E Szegezdi
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.